|
|
Article: Dr. Reddy's and ClinTec International Announce Co-Development of Anti-Cancer Compound DRF 1042.
- Article from:
- Business Wire
- Article date:
- September 27, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HYDERABAD, India & WINDSOR, England -- Dr. Reddy's Laboratories (NYSE: RDY) and ClinTec International announced today that they have entered into an agreement for the joint development of an anti-cancer compound, DRF 1042, belonging to the Topoisomerase inhibitors class of compounds for use as potential treatment of various types of cancer.
Dr. Reddy's has completed Phase I clinical trials for DRF 1042 in India. Under the terms of the agreement, Dr. Reddy's and ClinTec International will co-develop DRF 1042; undertaking Phase II and Phase III clinical trials, with the aim of securing USFDA and EMEA approvals.
Under the terms of the agreement, Dr. Reddy's ...